A ¥598 'Gout Cure' Was Seven Yuan of Factory Waste. Its Maker Now Owes ¥380 Million

The product was called a 'peptide and turmeric pressed candy,' and it promised something pressed candy normally does not: relief from gout. When a Hangzhou buyer identified only by her surname, Zhou, took the 598-yuan box for two weeks, her urine turned yellow and foamy and her heart began to race. Tests later found the real ingredient was not any peptide. It was febuxostat impurity K, the industrial residue left over from making febuxostat, a prescription medication for gout.

The arithmetic of the scheme is the part that makes it trend. The box cost roughly 7.48 yuan to manufacture, according to investigators quoted by Baidu; it left the factory to the brand at 60 yuan and retailed at 598 — an 80-fold markup from raw illegality to the shelf. The 'gout candy' was not a treatment at all. It was waste product dressed up as wellness, sold at the exact price point that signals seriousness to a worried patient.

Regulators did not stop at one box. What followed was a multi-city joint operation that led to a Guangzhou producer, Kangmaigu, identified as the source. The company's production license was revoked and the maker was fined and had 380 million yuan confiscated, with responsible individuals handed over for possible criminal charges. It is the kind of penalty Chinese regulators reach for when a case stops being a consumer complaint and becomes a public-health warning.

The story lands against a specific backdrop. Gout has become a booming theme in China's supplement industry, driven by an older generation of men raised on rich food and baijiu, and by a younger cohort discovering the condition early. Search 'gout' on any Chinese e-commerce site and shelves fill up with capsules, teas, and candies promising to lower uric acid — most of them food products, which means they face almost none of the testing a real drug would. That regulatory seam is exactly where a 7-yuan box of candy can become a 598-yuan 'cure.'

What makes this case sharper than a routine fake-medicine story is the nature of the active ingredient. Febuxostat impurity K is not just an unapproved additive; it is the leftover of the real drug's manufacturing process, present in the candy because it was cheap to obtain and carried a faint trace of the genuine article's effect. The person buying it was, in effect, paying prescription prices for industrial runoff. The fine is large because the harm is countable, and because the moment a supplement claims to treat a disease, China's drug law stops treating it gently.

The open question is the one every crackdown leaves behind. One producer has been shut and punished, but the shelf-space is still there, the search demand is still there, and the margin between a health food and an unproven cure remains wider than the language on the box would suggest. Zhou's complaint started with foamy urine and ended with a 380-million-yuan penalty; the next person's complaint should not have to get that far.